NCT03736863

A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 147 (estimated)
• Sponsor: The First Affiliated Hospital of Zhengzhou University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to observe and evaluate the efficacy and safety of multiple drug combinations in the treatment of advanced esophageal squamous cell carcinoma.

Detailed description

Immunotherapy has been widely used in patients with advanced esophageal cancer. Immunochemotherapy has become the standard treatment for advanced esophageal squamous cell carcinoma. The common second-line standard treatment is immunotherapy or chemotherapy, but that are established according to the medical evidence after the progression of chemotherapy, the preferred treatment plan after immuno-resistance needs to be explored. The purpose of this study was to explore the efficacy and safety of different drug combinations in patients with advanced esophageal cancer.

Conditions

• Esophageal Cancer

Interventions

Type	Name	Description
DRUG	Apatinib+ SHR-1210（Camrelizumab）	Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab）200 mg，Intravenous injection，q2W
DRUG	Apatinib+ SHR-1316（Adebrelimab）	Apatinib 250mg, q.d.po+SHR-1316（Adebrelimab） 1200 mg，Intravenous injection，q2W
DRUG	SHR-1316（Adebrelimab）+SHR-A2009	SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W,

Timeline

• Start date: 2019-12-05
• Primary completion: 2021-06-20
• Completion: 2025-12-30
• First posted: 2018-11-09
• Last updated: 2024-09-19

Locations

1 site across 1 country: China